4Moving Biotech is a clinical-stage biopharmaceutical company dedicated to pioneering research and development in the field of osteoarthritis (OA). Founded in 2020, the company focuses on creating first-in-class breakthrough therapies to address the unmet medical needs of OA patients. Its mission centers on restoring mobility to improve the quality of life for individuals affected by this condition.
The company's therapeutic strategy involves developing disease-modifying osteoarthritis drugs (DMOADs). A key candidate in its pipeline is 4P004, which is being investigated as a potential first-in-class GLP-1 therapy specifically targeting knee osteoarthritis. This approach aims to provide novel treatment options beyond symptomatic relief by targeting the underlying disease mechanisms.
4Moving Biotech has advanced its lead candidate, 4P004, into clinical development. The company recently announced the enrollment of the first patient in a Phase 2a trial for this therapy, marking a significant step in its development. This progression follows the receipt of an FDA Investigational New Drug (IND) clearance, which permits the initiation of clinical studies in the United States.
To support its ongoing research and development efforts, 4Moving Biotech successfully closed a €12 million financing round. This funding is intended to further advance its DMOAD pipeline, particularly its first-in-class candidate for knee osteoarthritis. The company operates from its headquarters located in Lille, Nord-Pas-de-Calais, France, contributing to the European biotech ecosystem.
